The National Institute of Allergy and Infectious Diseases (NIAID) recognizes the continuing threat of antimicrobial resistance and the need to develop new therapeutics and strategies to combat multidrug resistant organisms. NIAID leverages multiple mechanisms to help support antibiotic developers struggling in the “valley of death” of preclinical antibiotic development. The Division of Microbiology and Infectious Diseases’ (DMID) preclinical services are a comprehensive set of services to facilitate efforts to develop vaccines, diagnostics, and therapeutics for a broad array of bacterial, viral, fungal, and parasitic pathogens. These services are available to investigators worldwide at no charge.

中文翻译：

---

NIAID的抗生素开发综合支持机制。

美国国家过敏和传染病研究所（NIAID）认识到抗菌素耐药性的持续威胁，并认识到需要开发新的疗法和策略来对抗具有多种耐药性的生物。NIAID利用多种机制来帮助支持在临床前抗生素开发的“死亡谷”中挣扎的抗生素开发人员。微生物学和传染病学分部（DMID）的临床前服务是一整套综合服务，可促进为各种细菌，病毒，真菌和寄生虫病原体开发疫苗，诊断剂和治疗剂的努力。这些服务免费提供给全世界的研究人员。